Product Description
Lentiviral FVIII Gene Therapy for hemophilia A (Sourced from: http://szgimi.org/en/showproject.php?id=305)
Mechanisms of Action: Gene Therapy, FVIII
Novel Mechanism: No
Modality: Gene Therapy
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shenzhen Geno-Immune Medical Institute
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hemophilia A
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03217032 |
GIMI-IRB-17007 | P1 |
Unknown status |
Hemophilia A |
2022-05-31 |
2022-06-03 |
Recent News Events
Date |
Type |
Title |
|---|